Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orteronel + Docetaxel + Prednisone in mCRPC
NCT01084655Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jul 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orteronel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Millennium Pharmaceuticals. Started Jul 2010; status: completed.
02
Drugs
orteronel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01084655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01084655.